About The Study: The Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved) risk models demonstrated good performance in Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF). Baseline risk did not modify the relative treatment effect of finerenone.
Corresponding Author: To contact the corresponding author, John J. V. McMurray, MD, email john.mcmurray@glasgow.ac.uk .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2026.1049)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the American College of Cardiology 75th Annual Scientific Session & Expo.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2026.1049?guestAccessKey=b7cc855d-7727-437c-afd4-a567b0b078f6&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=032826
JAMA Cardiology